文献速递胸部肿瘤

血清肿瘤标志物预测中国非小细胞肺癌患者EGFR突变与ALK阳性的价值

Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
PubMed 文献 · Eur J Cancer · 2019-11-07

该回顾性分析纳入1089例治疗前完成EGFR/ALK检测及血清肿瘤标志物(STM)测定的中国非小细胞肺癌患者,评估STM预测驱动基因状态的价值。多因素分析显示腺癌、从不吸烟及CA125、SCC阴性是EGFR突变预测因素,联合模型AUC为0.715;年轻和从不吸烟是ALK阳性独立预测因素,联合模型AUC为0.760,STM不能预测ALK阳性。

要点

  • 腺癌、从不吸烟、CA125阴性、SCC阴性是EGFR突变的预测因素。
  • 四因素联合预测EGFR突变的AUC为0.715(95%CI 0.673-0.758)。
  • 年轻和从不吸烟是ALK阳性的独立预测因素,STM不能预测ALK阳性。

核心结论

  • STM与EGFR突变状态相关,可结合其他临床因素提高区分EGFR突变的能力。
  • 对于ALK阳性,年轻和从不吸烟状态可预测突变状态,而STM不能。

研究设计与样本

  • 回顾性分析纳入1089例治疗前接受EGFR或ALK检测及STM测定的中国NSCLC患者。
  • 比较亚组间临床特征和STM差异,采用多因素logistic回归识别预测因素。

主要发现

  • EGFR突变在女性(63.11%)、从不吸烟者(59.69%)和肺腺癌(53.87%)中更常见。
  • CA125、FERR、SCC和CYFRA 21-1阴性水平与EGFR突变显著相关(p<0.05)。
  • ALK阳性在年轻患者(中位年龄49岁)、女性(8.40%)、从不吸烟者(8.82%)和CEA阴性者(8.02%)中更常见。

关键数值与推荐

  • 多因素分析显示腺癌、从不吸烟、CA125阴性和SCC阴性是EGFR突变的预测因素(p<0.05)。
  • 四因素联合预测EGFR突变的ROC曲线AUC为0.715(95%CI 0.673-0.758)。
  • 多因素分析显示年轻和从不吸烟是ALK阳性的唯一独立预测因素(p<0.05)。
  • 两因素联合预测ALK阳性的ROC曲线AUC为0.760(95%CI 0.677-0.844)。

临床怎么用

  • 可结合腺癌、从不吸烟、CA125阴性和SCC阴性等临床因素辅助预判EGFR突变状态。
  • STM不宜用于预测ALK阳性,ALK检测仍应依据标准分子检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of serum tumor markers (STMs) in the modern management of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung cancer remains poorly described. In this study, we investigated whether STMs could be a valuable noninvasive tool to predict EGFR mutations and ALK positivity in non-small-cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: We retrospectively reviewed and included 1089 NSCLC patients who underwent EGFR or ALK mutation testing and STMs measurement prior to treatment. The differences in several clinical characteristics and STMs between the subgroups were analyzed. Multivariate logistic regression analysis was performed to identify predictors of EGFR mutations and ALK positivity. RESULTS: EGFR mutations were found more frequently in females (63.11%), never-smokers (59.69%), and those with lung adenocarcinoma (ADC) (53.87%). Negative carbohydrate antigen (CA) 125, ferritin (FERR), squamous cell carcinoma antigen (SCC), and soluble fragment of cytokeratin 19 (CYFRA 21-1) levels were significantly associated with EGFR mutations (p < 0.05). Multivariate analysis demonstrated that ADC, never-smoker status, and negative CA 125 and SCC results were predictors of EGFR mutations (p < 0.05). The receiver operating characteristic (ROC) curve yielded an area under the curve (AUC) of 0.715 (95% confidence interval [CI]: 0.673-0.758) for the combination of the four factors. Positive ALK expression was found more frequently in younger patients (median age: 49 years), females (8.40%), never-smokers (8.82%), and those negative for carcinoembryonic antigen (CEA) (8.02%). Multivariate analysis demonstrated that younger age and never-smoker status were the only independent predictors of ALK positivity (p < 0.05). The ROC curve yielded an AUC of 0.760 (95% CI: 0.677-0.844) for the combination of these two factors. CONCLUSION: STMs are associated with mutant EGFR status and could be integrated with other clinical factors to enhance the ability to distinguish EGFR mutation status among NSCLC patients. For ALK-positive patients, younger age and never-smoker status could predict the mutation status, whereas STMs could not.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang S, Ma P, Ma G, et al. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis. Eur J Cancer. 2019. PMID: 31707279. doi:10.1016/j.ejca.2019.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。